Delcath Systems (Delcath Systems) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Apr. 28, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Delcath Systems EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Delcath Systems's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Delcath Systems's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Medical Devices subindustry, Delcath Systems's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Delcath Systems's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Delcath Systems's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Delcath Systems (NAS:DCTH) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Delcath Systems EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Delcath Systems's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Delcath Systems (Delcath Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (NAS:DCTH) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

DV3R:Germany

Address

1633 Broadway, Suite 22C, New York, NY, USA, 10019

Website

https://www.delcath.com

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Executives

Vojo Vukovic	officer: See Remarks	C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Gerard J Michel	director, officer: Chief Executive Officer	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Sandra Pennell	officer: See Remarks	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
David L. Hoffman	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
John Purpura	officer: EVP, Regulatory Affairs	600 FIFTH AVENUE, 23RD FLOOR, NEW YORK NY 10020
John Richard Sylvester	director	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Salamon Steven A J	director	25 ADMIRAL ROAD, TORONTO A6 M5R 2L4
Rosalind Advisors, Inc.	director, other: See Remarks	15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Kevin Muir	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Anthony Dias	officer: Vice President of Finance	C/O SEACHANGE INTERNATIONAL, 50 NAGOG PARK, ACTON MA 01720
Gil Aharon	director	15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Johnny John	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Elizabeth Czerepak	director	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Christine Padula	officer: See Remarks	C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Simon Pedder	director	1001 MAIN STREET, SUITE 600, BUFFALO NY 14203